Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Context Therapeutics ( (CNTX) ).
Context Therapeutics Inc. received a notification from Nasdaq on February 27, 2025, regarding non-compliance with the Minimum Bid Price Rule, as its stock price fell below $1.00 for 30 consecutive business days. Initially given until August 26, 2025, to regain compliance, the company was later granted an extension until February 23, 2026. By October 17, 2025, Context Therapeutics successfully met the requirement, maintaining a stock price of $1.00 or greater for 10 consecutive days, and Nasdaq has closed the matter.
The most recent analyst rating on (CNTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.
Spark’s Take on CNTX Stock
According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.
Context Therapeutics has significant financial challenges, with no revenue and consistent losses, heavily weighing down its overall score. Technical analysis shows neutral market momentum, while valuation metrics highlight unprofitability. However, the recent initiation of a Phase 1 trial offers some hope for future growth. Collectively, these factors result in a low overall stock score, reflecting the company’s current financial instability and speculative potential.
To see Spark’s full report on CNTX stock, click here.
More about Context Therapeutics
Average Trading Volume: 247,814
Technical Sentiment Signal: Buy
Current Market Cap: $129.2M
For a thorough assessment of CNTX stock, go to TipRanks’ Stock Analysis page.